CompletedPHASE1, PHASE2NCT01003106

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peter A Campochiaro, MD
Principal Investigator
Peter A Campochiaro, MD
Johns Hopkins University
Intervention
Ranibizumab 0.5mg (monthly)(drug)
Enrollment
81 enrolled
Eligibility
18 years · All sexes
Timeline
20092015

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01003106 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials